Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Morales, Eva ^a,b,c   Cots, Francesc ^a,d   Sala, Maria ^a,c   Comas, Mercè ^a,c   Belvis, Francesc ^a   Riu, Marta ^a,c,e   Salvadá, Margarita ^f   Grau, Santiago ^a   Horcajada, Juan P ^a   Montero, Maria Milagro ^a   Castells, Xavier ^a,c  

^a HOSPITAL DEL MAR   (Spain)

^b Del Mar University   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d UNIVERSITAT OBERTA DE CATALUNYA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f Laboratori de Referencia de Catalunya   (Spain)

Author keywords

Antimicrobial resistance; Economic analysis; Hospital cost; Multi drug resistance; Pseudomonas aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT;

AGED; ARTICLE; COST; CROSS INFECTION; DRUG EFFECT; ECONOMICS; FEMALE; HOSPITAL COST; HOSPITALIZATION; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; SPAIN; STATISTICAL MODEL; TEACHING HOSPITAL;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COSTS AND COST ANALYSIS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SPAIN;

EID: 84861331849     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-122     Document Type: Article

References (24)

1. Consequences of bacterial resistance to antibiotics in medical practice. Acar JF, Clin Infect Dis 1997 24 17 S18 10.1093/clinids/24.Supplement-1.S17 8994777
2. Epidemiology of drug resistance: implications for a post-antimicrobial era. Cohen ML, Science 1992 257 1050 1055 10.1126/science.257.5073.1050 1509255
3. The current state of multidrug-resistant gram-negative bacilli in North America. Nicasio AM, Kuti JL, Nicolau DP, Pharmacotherapy 2008 28 235 249 10.1592/phco.28.2.235 18225969 (Pubitemid 351206969)
4. Antimicrobial Availability Task Force of the Infectious Diseases Society of America: Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Barlett JG, Clin Infect Dis 2006 42 657 668 10.1086/499819 16447111 (Pubitemid 43271379)
5. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Souli M, Galani I, Giamarellou H, Euro Surveill 2008 13 47) 1 11 pii: 19045
6. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the centers for disease control and prevention, 2006-2007. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, Infect Control Hosp Epidemiol 2008 29 996 1011 10.1086/591861 18947320
7. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Tacconelli E, Tumbarello M, Bertagnolio S, Citton R, Spanu T, Fadda G, Cauda R, Emerg Infect Dis 2002 8 220 221 10.3201/eid0802.010121 11897080 (Pubitemid 34202451)
8. Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study. Montero M, Sala M, Riu M, Belvis F, Salvado M, Grau S, Horcajada JP, Alvarez-Lerma F, Terradas R, Orozco-Levi M, et al. Eur J Clin Microbiol Infect Dis 2010 29 335 339 10.1007/s10096-009-0850-1 20033749
9. Pseudomonas aeruginosa: health and economic impact of antibiotic resistance and emergence of resistance. Carmeli Y, Troillet N, Karchmer AW, Samore MH, Arch Intern Med 1999 159 1127 1132 10.1001/archinte.159.10.1127 10335691 (Pubitemid 29230866)
10. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Montero M, Domínguez M, Orozco-Levi M, Salvadá M, Knobel H, Infection 2009 37 16 19 10.1007/s15010-008-8125- 9 19139809
11. Epidemiology and clinical outcomes of patient with multiresistant Pseudomonas aeruginosa. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y, Clin Infect Dis 1999 28 1128 1133 10.1086/514760 10452647 (Pubitemid 29203551)
12. Hospital economic impact of an outbreak of Pseudomonas aeruginosa infections. Bou R, Lorente L, Aguilar A, Perpĩán J, Ramos P, Peris M, Gonzalez D, J Hosp Infect 2009 71 138 142 10.1016/j.jhin.2008.07.018 18799237
13. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Cosgrove SE, Clin Infect Dis 2006 42 82 S89 10.1086/499406 16355321 (Pubitemid 43054219)
14. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Montero M, Horcajada JP, Sorlí L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H, Infection 2009 37 461 465 10.1007/s15010-009-8342-x 19499183
15. All Patient Refined Diagnosis Related Groups (APR-DRGs), Methodology Overview 3M Health Information Systems, Wallingford, CT 1998
16. Cost accounting and budgeting. Chandler IR, Fetter RB, Newbold RC, DRGs. Their design and development Michigan: Health Administration Press, Ann Arbor, Fetter RB, Brand DA, Gamache D, 1991
17. Risk adjustment: beyond patient classification systems. Cots F, Castells X, Mercadé L, Torre P, Riu M, Gac Sanit 2001 15 423 431 11734155
18. Investigating DRG cost weights for hospitals in middle income countries. Ghaffari S, Doran C, Wilson A, Aisbett C, Jackson T, Int J Health Plann Manage 2009 24 251 264 10.1002/hpm.948 18536005
19. Managing the stages of hospital cost accounting. Young DW, Pearlman LK, Healthc Financ Manage 1993 47 58 80 10145914 (Pubitemid 23142035)
20. Activity-based costing for hospitals. Udpa S, Health Care Manag Rev 1996 21 83 96 (Pubitemid 126432518)
21. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. Falagas ME, Koletsi PK, Bliziotis IA, J Med Microbiol 2006 55 1615 1617 10.1099/jmm.0.46884-0 17108262 (Pubitemid 44902022)
22. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO, Infect Control Hosp Epidemiol 2006 27 893 900 10.1086/507274 16941312 (Pubitemid 44449245)
23. Nosocomial infection, length of stay, and time-dependent bias. Beyersmann J, Kneib T, Schumacher M, Gastmeier P, Infect Control Hosp Epidemiol 2009 30 273 276 10.1086/596020 19193018
24. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods. Roberts RR, Scott RD, Hota B, Kampe LM, Abbasi F, Schabowski S, Ahmad I, Ciavarella GG, Cordell R, Solomon SL, Hagtvedt R, Weinstein RA, Med Care 2010 48 1026 1035 10.1097/MLR. 0b013e3181ef60a2 20940650